Pierre Marie`s Disease. Past and present
Abstract
The review is devoted to memorable date - 130-year registration of new medical entity - acromegaly, which is, due to its author P. Marie, not only promoted determination of physiological and pathological role of hypophysis in life activities, but also created conditions for
Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin
degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over,
pilot study
Abstract
Aims . To compare glucose variability in patients with type 1 diabetes (T1D) treated with insulin glargine (IGla) versus insulin degludec (IDeg) using continuous glucose monitoring (CGM). Methods. 13 patients with T1D were randomly assigned to receive IDeg once - daily
Assessment of the variability of glycemia, application of sitagliptin compared to placebo, in patients
with diabetes type 2 diabetes with inadequate glycemic control on treatment with metformin
Abstract
Aim. To evaluate glycemic variability during therapy sitagliptin 50 mg 2 times a day in combination with metformin 1000 mg two times a day compared to placebo in combination with metformin 1000 mg two times a day. Material and methods. A randomized, double - blind, placebo -
The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial
Abstract
Aims. Weight loss improves glycaemic control in type 2 diabetes mellitus (T2DM). However, as achieving and maintaining weight loss is difficult, alternative strategies are needed. Our primary aim was to investigate the effects of intermittent energy restriction (IER)
The role of drugs for weight reduction in stages management of type 2 diabetes: focus on sibutramine
Abstract
Authors of the article present the epidemiological and pathogenetic aspects of the relationship of type 2 diabetes and obesity, argue for the possibility of including drugs for weight loss in the current recommendations for the treatment of type 2 diabetes with obesity. We
Metabolic therapy of diabetic neuropathy by acetil-L-carnitine
Abstract
In this work has been defined the influence of protracted course of therapy (24 weeks) by acetyl-L-carnitine (Carnicetine) in a dose of 1500 mg/day on clinical implications of polyneuropathy and microvascular blood flow in patients with a diabetes mellitus type 2. 45
Correlation of serum leptin level with clinic and metabolic parameters in patients with different variants of primary revealed prediabetes
Abstract
Цель - определение возможных взаимосвязей уровня лептина плазмы с клинико - метаболическими параметрами пациентов с различными вариантами впервые выявленных ранних нарушений углеводного обмена. Результаты. Среди впервые выявленных вариантов предиабета доля нарушения
Prophylaxis of diabetes mellitus type 2: the role and
place of Metformin
Abstract
These cLinicaL guideLines were deveLoped by the medicaL experts of the Russian Association of Endocrino-Logists (members of the Advisory Group arein the Appendix A1). February 2015, kick off meeting of the Advisory Group under the chairmanship of Professor ALexander S.